Possible acute rejection associated with the use of the new antihepatitis C virus medications
Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new directacting antiviral agents gave big hopes to both clinicians and patients that they can overcome this...
Enregistré dans:
Auteurs principaux: | Khaled Ar Karkout, Saleema Al Sherif, Qutaiba Hussein, Alia Albawardi, Yousef Boobes |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2019
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/f31e5abbef6b427fbb755c5d33f5dd8e |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
par: Pol S, et autres
Publié: (2016) -
Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
par: Mohamed G. Mohamed, et autres
Publié: (2021) -
The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
par: Irina RUSU, et autres
Publié: (2020) -
CHEMOKINE MARKERS ASSOCIATED WITH EARLY REJECTION OF KIDNEY ALLOGRAFT
par: T. V. Fedorenko, et autres
Publié: (2019) -
Spot Urine Protein Excretion in the First Year Following Kidney Transplantation Associates With Allograft Rejection Phenotype at 1-Year Surveillance Biopsies: An Observational National-Cohort Study
par: Manca Oblak, et autres
Publié: (2021)